Compounded GLP-1s: The Real Quality and Regulatory Questions

Why we won't just say "compounded is bad"

The honest position on compounded GLP-1s is neither "identical to the branded drug" nor "poison." It's more useful, and more accurate, to explain the actual regulatory and quality issues so you can judge a specific product and pharmacy. Some compounded medicines, made by reputable pharmacies for legitimate reasons, are appropriate. Others — sold online with minimal oversight, using unapproved ingredients — carry serious, documented risks. The difference is knowable if you ask the right questions. → GLP-1 hub

FDA-approved vs compounded — what the distinction really means

FDA-approved semaglutide (Wegovy/Ozempic/Rybelsus) and tirzepatide (Zepbound/Mounjaro) go through review of the molecule's safety and efficacy and the manufacturer's production, sterility, potency and consistency. Every batch is made to that standard.

Compounded drugs are prepared by a pharmacy for an individual need. Compounding is a legitimate, long-standing part of medicine — but a compounded drug is not FDA-approved, is not reviewed batch-by-batch, and its quality depends heavily on the pharmacy that makes it. The FDA does not verify that a given compounded vial contains what its label says. That is the core distinction: not "fake versus real," but "individually assured by a pharmacy" versus "reviewed and standardized by the FDA." Grade A 🟢 (regulatory fact).

The shortage context — and why it shifts

Large-scale compounding of GLP-1s expanded because the branded drugs were placed on the FDA drug-shortage list. Under specific rules, compounders may prepare a drug that is otherwise commercially available when it's in shortage. That created a legal window and a large market.

The critical, frequently-missed point: when a drug comes off the shortage list, the legal basis for compounding it narrows or closes. That has now happened: the FDA declared the shortages resolved (tirzepatide in December 2024, semaglutide in February 2025), and the enforcement grace periods ended in mid-2025. As a result, routine mass-compounding of what are essentially copies of these drugs is no longer permitted — 503A and 503B pharmacies may compound them only in narrow, patient-specific circumstances (for example, a documented clinical need the approved product can't meet). Compounded versions remain non-FDA-approved, and some telehealth "personalized-dose" workarounds are legally contested. Status here remains time-sensitive; re-check at the point of care. Grade B 🟡

503A vs 503B — who is making it

Two very different kinds of pharmacy operate under different rules:

• 503A compounding pharmacies — traditional pharmacies compounding for an individual patient prescription. Overseen mainly by state boards of pharmacy, not routinely FDA-inspected for manufacturing.
• 503B outsourcing facilities — register with the FDA, are subject to federal Good Manufacturing Practice (cGMP) standards and FDA inspection, and can make larger batches. Generally a higher, more consistent quality bar than 503A.

Neither produces an FDA-approved product, but a 503B outsourcing facility operates under stricter, federally-inspected quality controls than a typical 503A pharmacy — and far above an unregulated online seller. Knowing which one made your product is one of the most informative questions you can ask. Grade B 🟡

Quality and sterility concerns

GLP-1s are injectable, so sterility is not optional. The documented quality issues with compounded and grey-market products include:

• Contamination / non-sterility — a real hazard for any injectable made outside rigorous controls.
• Sub- or super-potency — the vial containing less or more active drug than labeled, from imprecise formulation.
• Impurities and degradation — from poor-quality active ingredient or improper storage and reconstitution.
• Inadequate stability data — how long the product stays potent and sterile after mixing may be unknown.

These are not hypothetical; they are the predictable failure modes when batch-level FDA review is absent and the pharmacy's own standards become the only safeguard. Grade B 🟡

Dosing errors — a leading real-world harm

Some of the best-documented harm from compounded GLP-1s has been dosing errors, not exotic toxicity. Why they happen:

• Compounded products come in different concentrations than the branded pens, so a "unit" or "click" from one product doesn't equal another.
• Patients may draw up doses from multi-dose vials with syringes, inviting ten-fold errors (e.g., confusing units with milligrams or milliliters).
• Instructions vary by pharmacy, and error-resistant pen devices that the branded products use are often absent.

Overdoses have caused severe nausea, vomiting, dehydration and hospital visits. This is a product-design and instruction problem as much as a chemistry one. Grade B 🟡

EVIDENCE CARD · Compounded GLP-1 safety

• WHAT'S SHOWN: Compounded GLP-1s are not FDA-approved or batch-reviewed; documented harms include dosing errors, and quality/sterility varies by pharmacy. Regulators have warned about unapproved salt forms and counterfeits.
• WHAT'S UNKNOWN: The true rate of harm across the many products and pharmacies; the potency, sterility and stability of any specific unverified vial.
• OUR POSITION: Not uniformly dangerous, but quality assurance shifts to the pharmacy. Source matters enormously — a 503B facility differs from an online grey-market seller. Prefer FDA-approved products; if compounded is used, vet the pharmacy hard. Grade B 🟡

Salt forms — semaglutide sodium and semaglutide acetate

This is a specific, important issue. The approved products contain semaglutide as the studied base molecule. Some compounded and grey-market products have used salt forms — semaglutide sodium or semaglutide acetate.

• These salt forms are not the same as the FDA-approved active ingredient, and the FDA has stated they are not shown to be safe and effective and generally should not be used in compounding.
• Salt forms have sometimes been sold as if equivalent, or marketed as "research use only" peptides to sidestep oversight.
• The efficacy and safety of these forms have not been established the way the approved base molecule has.

If a product is labeled "semaglutide sodium," "semaglutide acetate," or "research/not for human use," that is a significant red flag. Grade C 🟠 (safety/efficacy of salt forms not established).

Counterfeits and the grey market

Beyond legitimate compounding lies an entirely separate danger: counterfeit and grey-market products — fake branded pens, "peptides" sold online, and vials of unknown origin. These may contain the wrong amount of drug, the wrong substance, or contaminants. Regulators have seized counterfeit GLP-1 pens. This is a different problem from a licensed compounding pharmacy, and the highest-risk category. If a deal looks too cheap, comes from an unverified website, or ships "research chemicals," assume the worst. Grade B 🟡

Legitimate reasons compounding sometimes has a role

To stay balanced: compounding isn't inherently illegitimate. Reasonable scenarios include a documented allergy or intolerance to an inactive ingredient in the approved product, a specific formulation need, or genuine, current shortage of the approved drug under the applicable rules. The key is that these are clinically justified, pharmacist-supervised situations — not "cheaper Ozempic from a website." When compounding is used, a 503B outsourcing facility and a transparent, verifiable pharmacy are the safer path. Grade C 🟠

What patients should ask a pharmacy

If you are considering or using a compounded GLP-1, ask directly:

1. Is this an FDA-approved product or compounded? (Get a clear answer.)
2. Are you a 503A pharmacy or a 503B outsourcing facility? Are you licensed, and in what state?
3. What exact ingredient is used — semaglutide/tirzepatide base, or a salt form (sodium/acetate)? Avoid salt forms and "research" peptides.
4. What is the concentration, and how is my dose measured (pen vs vial-and-syringe)? Get written dosing instructions.
5. What sterility, potency and stability testing does each batch undergo, and can I see a certificate of analysis?
6. How should it be stored, and what's the beyond-use date after mixing?
7. Who supervises this prescription clinically, and how are adverse effects handled?

A pharmacy that answers these transparently is a very different proposition from one that won't. Grade B 🟡

SIGNATURE — "What the evidence says: compounded GLP-1s"

• What we know: Compounded GLP-1s are not FDA-approved or batch-reviewed; dosing errors are a documented harm; salt forms and counterfeits are specific hazards; quality varies by pharmacy type (503A vs 503B) and legitimacy.
• What we think: Much of the risk is concentrated in the grey market and salt-form/"research" products rather than in every licensed compounder.
• What we don't know: The true rate of harm across products; the exact contents of any unverified vial; how shortage-driven rules will settle over time.
• What patients should do: Prefer FDA-approved products; if compounding is genuinely needed, use a verifiable, ideally 503B source, avoid salt forms and "research" peptides, insist on clear dosing, and never buy from unverified websites.

Questions patients ask

MYTHS & FAQ (≥20) — Compounded & grey-market GLP-1s

MYTH: "Compounded semaglutide is exactly the same as Wegovy." Short answer: Not established. Evidence: it isn't FDA-approved or batch-reviewed, and may differ in ingredient, concentration or purity. Bottom line: it may be similar or not — you can't assume equivalence. Grade B 🟡

MYTH: "If a pharmacy sells it, the FDA approved it." Short answer: No. Evidence: compounded drugs are not FDA-approved; the FDA doesn't review each batch. Bottom line: legality under compounding rules is not the same as FDA approval. Grade A 🟢

MYTH: "Compounded is automatically dangerous." Short answer: Overbroad. Evidence: a licensed 503B facility follows federal cGMP and inspection; risk is highest in the grey market. Bottom line: source and product determine risk. Grade B 🟡

MYTH: "All compounding pharmacies are equal." Short answer: No. Evidence: 503A pharmacies are state-overseen and not routinely FDA-inspected; 503B outsourcing facilities meet federal cGMP. Bottom line: ask which one made your product. Grade B 🟡

MYTH: "Semaglutide sodium is just semaglutide." Short answer: No. Evidence: salt forms are not the approved active ingredient and aren't shown safe and effective. Bottom line: avoid salt-form products. Grade C 🟠

MYTH: "'Research use only' peptides are a legal loophole worth using." Short answer: No. Evidence: they dodge oversight and are often salt forms or counterfeits of unknown content. Bottom line: among the riskiest sources. Grade B 🟡

MYTH: "Cheaper means the same drug at a better price." Short answer: Not reliably. Evidence: deep discounts often signal grey-market or counterfeit products. Bottom line: price alone tells you nothing about contents. Grade C 🟠

MYTH: "Compounded and branded doses are interchangeable clicks/units." Short answer: No. Evidence: concentrations differ between products, so a "unit" isn't universal. Bottom line: a leading cause of overdoses — follow product-specific written dosing. Grade B 🟡

MYTH: "Injecting a compounded vial is no riskier than a pen." Short answer: It can be. Evidence: injectables demand sterility, and vial-and-syringe dosing invites errors. Bottom line: sterility and dose-measurement risk rise without pen devices and batch review. Grade B 🟡

MYTH: "If I have side effects it can't be the product's quality." Short answer: It might be. Evidence: potency variation and dosing errors mimic or amplify side effects. Bottom line: severe or unexpected effects warrant checking the product and dose. Grade B 🟡

MYTH: "Counterfeit pens are basically the same as real ones." Short answer: No. Evidence: regulators have seized fakes with wrong or unknown contents. Bottom line: buy only through verified, legitimate channels. Grade B 🟡

MYTH: "There's never a legitimate reason to compound a GLP-1." Short answer: There can be. Evidence: documented intolerance to an inactive ingredient, or genuine shortage under the rules, are legitimate. Bottom line: legitimate use is clinically justified and pharmacist-supervised. Grade C 🟠

MYTH: "Compounding rules for these drugs never change." Short answer: They do — and they just did. Evidence: the legal basis narrows when a drug leaves the shortage list, and the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), with grace periods ending mid-2025; routine mass-compounding of essentially-copy products is no longer permitted. Bottom line: verify current status rather than assuming. Grade B 🟡

MYTH: "A certificate of analysis isn't something I can ask for." Short answer: You can. Evidence: reputable compounders test batches and can share results. Bottom line: ask for sterility/potency testing documentation. Grade B 🟡

MYTH: "Storage and expiry don't matter for peptides." Short answer: They do. Evidence: GLP-1 peptides degrade with improper storage, and mixed products have limited beyond-use dates. Bottom line: follow storage and expiry instructions precisely. Grade B 🟡

MYTH: "Online telehealth compounded programs are automatically safe." Short answer: Not automatically. Evidence: quality ranges from reputable 503B-sourced to grey-market. Bottom line: verify the actual pharmacy and ingredient behind the program. Grade C 🟠

MYTH: "Compounded tirzepatide is easier to verify than semaglutide." Short answer: No. Evidence: the same regulatory and quality concerns apply to compounded tirzepatide. Bottom line: same questions, same caution. Grade B 🟡 → Tirzepatide

MYTH: "If it's prescribed, dosing safety is guaranteed." Short answer: No. Evidence: many dosing errors occur with prescribed compounded vials. Bottom line: insist on clear written dosing and, ideally, error-resistant delivery. Grade B 🟡

MYTH: "The FDA tests my compounded vial before it ships." Short answer: No. Evidence: the FDA does not verify individual compounded batches. Bottom line: quality assurance is the pharmacy's job, not the FDA's, for compounded products. Grade A 🟢

MYTH: "Switching from branded to compounded won't change my results or risks." Short answer: It might. Evidence: differences in ingredient, concentration and quality can affect both efficacy and safety. Bottom line: treat a switch as a real clinical change, discussed with a clinician. Grade B 🟡

MYTH: "Asking the pharmacy hard questions is rude or pointless." Short answer: It's essential. Evidence: transparency about pharmacy type, ingredient, testing and dosing separates safer from riskier sources. Bottom line: a pharmacy that won't answer is itself an answer. Grade B 🟡

KEEP READING

• Semaglutide and Tirzepatide — the FDA-approved products and what they're studied to do.
• GLP-1 Side Effects — how product quality and dosing accuracy change the risk picture.
• Semaglutide vs Tirzepatide — choosing between the approved options.
• Should I Take a GLP-1? — a decision tool, not a sales funnel.

Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: 2026-08-10 · References: FDA guidance and statements on compounded semaglutide/tirzepatide, salt forms and drug-shortage compounding; 503A/503B statutory framework; regulatory alerts on counterfeit GLP-1 products. Regulatory and shortage status is time-sensitive — verify at point of care. Educational; not individualized medical advice.